UBS Group’s ImmunoCellular Therapeutics Ltd. IMUC.WS Stock Holding History

UBS Group’s Portfolio IMUC.WS Stock Details IMUC.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,995	Closed	–	–	8671
2018 Q3	$0	Buy	1,995 +1,895	+1,895%	+$46	﹤0.01%	8530
2018 Q2	$0	Buy	+100	New	+$2	﹤0.01%	8498
2018 Q1	–	Sell	-1,500	Closed	–	–	8440
2017 Q4	$0	Sell	1,500 -1,358	-48%	-$62	﹤0.01%	8317
2017 Q3	$0	Sell	2,858 -7,604	-73%	-$365	﹤0.01%	8224
2017 Q2	$0	Buy	10,462 +9,140	+691%	+$1.59K	﹤0.01%	8240
2017 Q1	$0	Buy	1,322 +100	+8%	+$52	﹤0.01%	8245
2016 Q4	$1K	Buy	+1,222	New	+$416	﹤0.01%	7688

UBS Group's IMUC.WS Position: Q4 2018 in Review

UBS Group sold out of ImmunoCellular Therapeutics Ltd. (IMUC.WS) in Q4 2018, closing a stake of 1,995 shares.

UBS Group first reported a position in IMUC.WS in Q4 2016 and held it in 7 quarters. The position peaked at $1K in Q4 2016. 0 funds tracked by Wall St. Rank hold IMUC.WS as of Q4 2018.

UBS Group reported no remaining ImmunoCellular Therapeutics Ltd. position as of Q4 2018 after selling out during the quarter.
UBS Group sold 1,995 ImmunoCellular Therapeutics Ltd. shares in Q4 2018.
UBS Group first reported a position in ImmunoCellular Therapeutics Ltd. in Q4 2016 and held it in 7 quarters.
UBS Group's ImmunoCellular Therapeutics Ltd. position peaked at $1K in Q4 2016.
0 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics Ltd. as of Q4 2018.

Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.